Nimotop (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This action relaxes the vessels, leading to vasodilation, improved cerebral perfusion, and a decrease in calcium‑induced neuronal injury that can follow a subarachnoid hemorrhage.

The dosage of Nimotop is determined by the prescribing clinician based on the patient’s condition, weight, and renal or hepatic function. The prescriber will specify the exact amount and frequency on the prescription label.

The safety of nimodipine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nimotop, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is distinguished by its preferential activity in cerebral vessels, whereas many other calcium‑channel blockers target systemic vasculature. This selectivity makes nimodipine especially suitable for preventing vasospasm after subarachnoid hemorrhage, while other agents are typically used for hypertension or angina.

Nimotop tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Nimotop is taken orally as a tablet, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless specifically instructed by a healthcare professional.

The most serious risks include severe hypotension, bradycardia, and rare but potentially life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of low blood pressure, abnormal heart rhythms, or any severe skin changes, and seek immediate medical attention if they occur.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any other dihydropyridine calcium‑channel blockers. Caution is also advised for individuals with severe hepatic impairment, uncontrolled hypotension, or those taking potent CYP3A4 inhibitors without appropriate medical supervision.